Benitec Biopharma (BNTC) Retained Earnings (2019 - 2025)
Benitec Biopharma (BNTC) has disclosed Retained Earnings for 7 consecutive years, with -$7.3 million as the latest value for Q1 2025.
- Quarterly Retained Earnings rose 96.04% to -$7.3 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was -$7.3 million through Mar 2025, up 96.04% year-over-year, with the annual reading at -$892000.0 for FY2024, 99.47% up from the prior year.
- Retained Earnings hit -$7.3 million in Q1 2025 for Benitec Biopharma, down from -$993000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$738000.0 in Q3 2022 to a low of -$185.5 million in Q1 2024.
- Historically, Retained Earnings has averaged -$79.8 million across 5 years, with a median of -$66.7 million in 2021.
- Biggest five-year swings in Retained Earnings: tumbled 23539.84% in 2023 and later surged 99.47% in 2024.
- Year by year, Retained Earnings stood at -$1.3 million in 2021, then rose by 29.46% to -$898000.0 in 2022, then tumbled by 20084.86% to -$181.3 million in 2023, then surged by 99.45% to -$993000.0 in 2024, then crashed by 639.38% to -$7.3 million in 2025.
- Business Quant data shows Retained Earnings for BNTC at -$7.3 million in Q1 2025, -$993000.0 in Q3 2024, and -$892000.0 in Q2 2024.